VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PLUR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PLURPluri Inc.
$2.07$19M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

PLUR logoPluri Inc.(PLUR)Earnings, Financials & Key Ratios

PLUR•NASDAQ
$2.07
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCell and Gene Therapy Developers
AboutPluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Show more
  • Revenue$1M+309.8%
  • EBITDA-$22M+0.2%
  • Net Income-$23M-8.1%
  • EPS (Diluted)-3.56+10.8%
  • Gross Margin48.95%-50.4%
  • EBITDA Margin-1636.23%+75.6%
  • Operating Margin-1659.88%+75.6%
  • Net Margin-1690.34%+73.6%
  • ROE-992.66%-392.2%

PLUR Price & Volume

Pluri Inc. (PLUR) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Losses Threaten Pluri Capital Solvency

Investment Thesis • Updated 2026Q3

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency

Key Thesis Takeaways

  • Pluri Inc.
  • faces a precarious financial outlook characterized by erratic revenue streams and a rapid depletion of its liquidity buffer.
  • The company's pivot toward CDMO services has yet to demonstrate scalability, as evidenced by the persistent inability to achieve positive operating margins.
  • Investors should remain cautious given the significant equity deficit and the ongoing reliance on debt to fund operations that continue to burn cash at a rate of approximately $5M per quarter.

Verdict Logic

the company's fundamental instability is underscored by a negative equity position of $18.6M and a consistent quarterly cash burn that necessitates urgent, non-dilutive capital to sustain operations.

PLUR Growth Metrics

Pluri Inc. (PLUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years13.43%
5 Years125.33%
3 Years78.73%
TTM4.35%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-26.31%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM25.45%

Return on Capital

10 Years-78.09%
5 Years-68.82%
3 Years-71.16%
Last Year-107.06%

PLUR Recent Earnings

Pluri Inc. (PLUR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (38%)●Beat Revenue 1/12 qtrs (14%)
Q1 2026Latest
Feb 12, 2026
Metric
Actual
Est
EPS
$0.71-9.2%
$0.65
Rev
$198,000-69.0%
$638,000
Q4 2025
Nov 12, 2025
Metric
Actual
Est
EPS
$0.65+12.2%
$0.74
Rev
$316,000-50.5%
$638,000
Q4 2025
Sep 17, 2025
Metric
Actual
Est
EPS
$2.62-303.1%
$0.65
Rev
$398,000-37.6%
$638,000
Q2 2025
May 13, 2025
Metric
Actual
Est
EPS
$0.94-28.8%
$0.73
Rev
$427,000+6.8%
$400,000
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 12, 2026
$0.71vs $0.65-9.2%
$198,000vs $638,000-69.0%
Q4 2025Nov 12, 2025
$0.65vs $0.74+12.2%
$316,000vs $638,000-50.5%
Q4 2025Sep 17, 2025
$2.62vs $0.65-303.1%
$398,000vs $638,000-37.6%
Q2 2025May 13, 2025
$0.94vs $0.73-28.8%
$427,000vs $400,000+6.8%
Based on last 12 quarters of dataView full earnings history →

Latest PLUR News

Recent stock market news and headlines for Pluri Inc. (PLUR)

Newsfile Corp·Jun 16, 2026
Plurilock Announces Results of Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecurity company, is pleased to announce the results of its Annual General Meeting (the "Meeting") of shareholders held on June 16, 2026. All resolutions presented to the shareholders were approved.

Peers Comparison

Key metrics vs top competitors for Pluri Inc. (PLUR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PLUR logoPLURPluri Inc.Current
$2.07$18.61M-0.58309.82%-1690.34%-992.66%—
FATE logoFATEFate Therapeutics, Inc.
$3.02$352.01M-2.63-51.24%-2056.79%-58.89%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$17.43$1.96B-4.5716.92%-597.04%-57.27%—
BEAM logoBEAMBeam Therapeutics Inc.
$37.92$3.9B-46.81120.01%-49.17%-5.89%—
EDIT logoEDITEditas Medicine, Inc.
$3.75$367.15M-2.0825.39%-281.59%-677.39%—
CRSP logoCRSPCRISPR Therapeutics AG
$60.77$5.86B-9.39-89.97%-13856.54%-30.88%—

Compare PLUR vs Peers

Pluri Inc. (PLUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for PLUR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PLUR against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, NTLA, BEAM, EDIT

PLUR SEC Filings & Documents

Pluri Inc. (PLUR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Mar 27, 2026·SEC

Material company update

Mar 2, 2026·SEC

Material company update

Jan 22, 2026·SEC

10-K Annual Reports

3
FY 2025

Sep 17, 2025·SEC

FY 2024

Sep 18, 2024·SEC

FY 2023

Sep 12, 2023·SEC

10-Q Quarterly Reports

6
FY 2026

May 14, 2026·SEC

FY 2026

Feb 12, 2026·SEC

FY 2025

Nov 12, 2025·SEC

Get notified when PLUR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PLUR Frequently Asked Questions

Pluri Inc. (PLUR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Pluri Inc.'s revenue?

Pluri Inc. (PLUR) reported $1.1M in revenue for fiscal year 2025.

How fast is Pluri Inc. growing?

Pluri Inc. (PLUR) grew revenue by 309.8% over the past year. This is strong growth.

Is PLUR profitable?

Pluri Inc. (PLUR) reported a net loss of $26.2M for fiscal year 2025.

Dividend & Returns
What is PLUR's return on equity?

Pluri Inc. (PLUR) has a return on equity (ROE) of -992.7%. Negative ROE indicates the company is unprofitable.

What is Pluri Inc.'s free cash flow?

Pluri Inc. (PLUR) had negative free cash flow of $21.7M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PLUR back in 2002?

Total return calculator · dividends reinvested · 24+ years of data

See returns →